CLK2 blockade modulates alternative splicing compromising MYC‐driven breast tumors
MYC oncogene overexpression/amplification is common in multiple human cancers, in which it regulates proliferation, apoptosis and cell metabolism, among other processes, and its expression associates with poor prognosis. Targeting MYC presents an exciting therapeutic possibility, but developing appr...
Main Authors: | Fernando Salvador, Roger R Gomis |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer Nature
2018-06-01
|
Series: | EMBO Molecular Medicine |
Online Access: | https://doi.org/10.15252/emmm.201809213 |
Similar Items
-
Anti‐tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC‐dependent vulnerability
by: Kenichi Iwai, et al.
Published: (2018-06-01) -
Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing.
by: Fedorov, O, et al.
Published: (2011) -
Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing.
by: Fedorov, O, et al.
Published: (2011) -
Pharmacological inhibition of CLK2 activates YAP by promoting alternative splicing of AMOTL2
by: Maya L Bulos, et al.
Published: (2023-12-01) -
CLK1/CLK2-driven signalling at the Leishmania kinetochore is captured by spatially referenced proximity phosphoproteomics
by: Vincent Geoghegan, et al.
Published: (2022-11-01)